Zou J - Search Results

1

Towards more accurate pharmacophore modeling: Multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2.

Zou J, Xie HZ, Yang SY, Chen JJ, Ren JX, Wei YQ. Zou J, et al. J Mol Graph Model. 2008 Nov;27(4):430-8. doi: 10.1016/j.jmgm.2008.07.004. Epub 2008 Aug 7. J Mol Graph Model. 2008. PMID: 18786843

2

Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process.

Zou J, Wang YD, Ma FX, Xiang ML, Shi B, Wei YQ, Yang SY. Zou J, et al. Proteins. 2008 Jul;72(1):323-32. doi: 10.1002/prot.21928. Proteins. 2008. PMID: 18214972

3

Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.

Xie HZ, Li LL, Ren JX, Zou J, Yang L, Wei YQ, Yang SY. Xie HZ, et al. Among authors: zou j. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1944-9. doi: 10.1016/j.bmcl.2009.02.049. Epub 2009 Feb 20. Bioorg Med Chem Lett. 2009. PMID: 19254842

4

Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.

Ren JX, Li LL, Zou J, Yang L, Yang JL, Yang SY. Ren JX, et al. Among authors: zou j. Eur J Med Chem. 2009 Nov;44(11):4259-65. doi: 10.1016/j.ejmech.2009.07.008. Epub 2009 Jul 16. Eur J Med Chem. 2009. PMID: 19640613

5

Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.

Yang LJ, Zou J, Xie HZ, Li LL, Wei YQ, Yang SY. Yang LJ, et al. Among authors: zou j. PLoS One. 2009 Dec 24;4(12):e8470. doi: 10.1371/journal.pone.0008470. PLoS One. 2009. PMID: 20041122 Free PMC article.

6

Integrated computational model of cell cycle and checkpoint reveals different essential roles of Aurora-A and Plk1 in mitotic entry.

Zou J, Luo SD, Wei YQ, Yang SY. Zou J, et al. Mol Biosyst. 2011 Jan;7(1):169-79. doi: 10.1039/c0mb00004c. Epub 2010 Oct 26. Mol Biosyst. 2011. PMID: 20978655

7

Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking.

Wan HL, Wang ZR, Li LL, Cheng C, Ji P, Liu JJ, Zhang H, Zou J, Yang SY. Wan HL, et al. Among authors: zou j. Chem Biol Drug Des. 2012 Sep;80(3):366-73. doi: 10.1111/j.1747-0285.2012.01415.x. Epub 2012 Jun 27. Chem Biol Drug Des. 2012. PMID: 22594639

8

Retrieving novel C5aR antagonists using a hybrid ligand-based virtual screening protocol based on SVM classification and pharmacophore models.

Qing XY, Zhang CH, Li LL, Ji P, Ma S, Wan HL, Wang ZR, Zou J, Yang SY. Qing XY, et al. Among authors: zou j. J Biomol Struct Dyn. 2013;31(2):215-23. doi: 10.1080/07391102.2012.698245. Epub 2012 Jul 25. J Biomol Struct Dyn. 2013. PMID: 22831459

9

Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.

Yang LL, Li GB, Yan HX, Sun QZ, Ma S, Ji P, Wang ZR, Feng S, Zou J, Yang SY. Yang LL, et al. Among authors: zou j. Eur J Med Chem. 2012 Oct;56:30-8. doi: 10.1016/j.ejmech.2012.08.007. Epub 2012 Aug 14. Eur J Med Chem. 2012. PMID: 22944772

10

Neighbor communities in drug combination networks characterize synergistic effect.

Zou J, Ji P, Zhao YL, Li LL, Wei YQ, Chen YZ, Yang SY. Zou J, et al. Mol Biosyst. 2012 Oct 30;8(12):3185-96. doi: 10.1039/c2mb25267h. Mol Biosyst. 2012. PMID: 23014807

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,353 results

Search Page

Filters